PIK3CD and Merkel cell skin cancer: Our group and others have detected activating mutations of PIK3CA and frequent activation of PI3K/AKT/mTOR pathway in MCC tumors, thus indicating PI3Ks and downstream signaling molecules are good therapeutic targets.